Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Abstract High lipoprotein (a)[Lp (a)] concentrations are one of the most important genetically
determined risk factors for cardiovascular disease. Lp (a) concentrations are an enigmatic …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

The initial studies focusing on lipoprotein (a)[Lp (a)] and its role in atherosclerotic
cardiovascular disease were conducted exclusively in Whites. Subsequently, multiple large …

Abstract In 2022, the European Atherosclerosis Society (EAS) published a new consensus
statement on lipoprotein (a)[Lp (a)], summarizing current knowledge about its causal …

Background Elevated lipoprotein (a) and familial hypercholesterolaemia are both
independent risk conditions for cardiovascular disease. Although signs of atherosclerosis …

BACKGROUND: Lipoprotein (a) is a risk factor for cardiovascular events and modifies the
benefit of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Lipoprotein (a) …

Abstract Background Elevated lipoprotein (a)(Lp [a]) concentrations are associated with
increased cardiovascular event risk even in the presence of well-controlled low-density …

Abstract Lipoprotein (a)[Lp (a)], a distinct lipoprotein class, has become a major focus for
cardiovascular research. This review is written in light of the recent guideline and consensus …

Since the contribution of high Lp (a) concentrations to global ASCVD risk has been
underestimated in the past, a clear recommendation to measure Lp (a) at least once in a …